A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Aged 18 to 65 years, inclusive, at the time of signing the ICF. * Body mass index between 18.0 and 30.5 kg/m2, inclusive. * No clinically significant findings on screening evaluations (clinical, laboratory, and ECG). * Ability to swallow and retain oral medication. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening. * Participants with any history of an autoimmune disease diagnosis. * History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension. * History or presence of an abnormal ECG. * Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's disease or chronic pancreatitis). * Any malignancies or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ. * Current or recent (within 3 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy; excluding appendectomy and hernia repair) that could affect the absorption of study drug. * Any major surgery within 4 weeks of screening. * Donation of blood to a blood bank or…